Arvee Laborat.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 17-Aug, Arvee Laboratories (India) Ltd's stock price is 165.55, down 0.28%. Despite recent short-term gains, the stock has a significant year-to-date decline of 22.40%, with reduced trading volume indicating decreased investor confidence.

As of 17-Aug, Arvee Laboratories (India) Ltd's stock price is currently at 165.55, reflecting a decrease of 0.46, or 0.28%. This decline can be attributed to several factors. <BR><BR>Despite a positive performance over the past week and month, where the stock has risen by 6.74% and 4.77% respectively, it has experienced a significant year-to-date decline of 22.40%. This suggests that while there may have been short-term gains, the overall trend for the year has been negative. <BR><BR>Additionally, today's trading activity indicates a falling investor participation, with delivery volume on 14 August dropping by 83.6% compared to the 5-day average. This sharp decline in trading volume may signal decreased investor interest or confidence in the stock, contributing to the downward price movement. <BR><BR>Moreover, while the stock is performing inline with its sector today, it is trading below its 5-day and 200-day moving averages, which could indicate a bearish sentiment among investors. Overall, the combination of a significant year-to-date decline, reduced trading volume, and positioning relative to moving averages suggests that the stock is currently facing downward pressure.

Which are the latest news on Arvee Laborat.?

Who are in the management team of Arvee Laborat.?

The management team of Arvee Laborat includes Shalin Sudhakarbhai Patel (Chairman & Managing Director), Shalin Bharat Chokshi (Whole-time Director), and several Independent Directors: Chandrakala Ashok Bhatt, Vishal Nitin Mehta, Amishkumar Maheshkumar Shah, Paragbhai Manubhai Shah, Neetu Jalan, and Sachin Kanwarlal Kansal.

The management team of Arvee Laborat includes the following individuals:<BR><BR>1. **Shalin Sudhakarbhai Patel** - Chairman & Managing Director<BR>2. **Shalin Bharat Chokshi** - Whole-time Director<BR>3. **Chandrakala Ashok Bhatt** - Independent Director<BR>4. **Vishal Nitin Mehta** - Independent Director<BR>5. **Amishkumar Maheshkumar Shah** - Independent Director<BR>6. **Paragbhai Manubhai Shah** - Independent Director<BR>7. **Neetu Jalan** - Independent Director<BR>8. **Sachin Kanwarlal Kansal** - Independent Director<BR><BR>If you need more specific details about any of these individuals or their roles, feel free to ask!

What does Arvee Laborat. do?

Arvee Laboratories (India) Ltd manufactures specialized chemicals and operates in the Chemicals & Petrochemicals industry as a Micro Cap company. As of June 2026, it reported net sales of 17 Cr and a net profit of 2 Cr, with a market cap of INR 194 Cr.

Overview: <BR>Arvee Laboratories (India) Ltd is engaged in the manufacturing of specialized chemicals and operates within the Chemicals & Petrochemicals industry, classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 2012 as a Private Limited Company and later renamed to Arvee Laboratories (India) Limited in 2017. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 17 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 194 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 46.00 <BR>Industry P/E: 44 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.06 <BR>Return on Equity: 11.99% <BR>Price to Book: 5.78 <BR><BR>Contact Details: <BR>Address: 49/3 B Shyamal Row House, 100 Feet Road Satellite Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-26749036/37/38 <BR>Email: shalin.patel@arveelabs.com <BR>Website: http://www.arveelabs.com

Who are the peers of the Arvee Laborat.?

Arvee Laborat.'s peers include Sanginita Chemi., Ushanti Colour, and Indian Phosphate, among others. Its management risk is below average, growth is rated below average, and its 1-year return is -0.72%, better than Hi-Green Carbon but significantly lower than Sanginita Chemi.'s 440.44%.

Peers: The peers of Arvee Laborat. are Sanginita Chemi., Ushanti Colour, Hi-Green Carbon, Mahickra Chem., Indian Phosphate, Vital Chemtech, Jocil, Par Drugs & Che., Hindcon Chemical, and Nilachal Carbo.<BR><BR>Quality Snapshot: Excellent management risk is observed at Indian Phosphate, Jocil, and Par Drugs & Che., while Average management risk is found at Mahickra Chem., Hindcon Chemical, and the rest. Below Average management risk is noted for Sanginita Chemi., Ushanti Colour, Hi-Green Carbon, Arvee Laborat., and Vital Chemtech. Growth is rated as Excellent for Indian Phosphate, Jocil, and Par Drugs & Che., Average for Mahickra Chem. and Hindcon Chemical, and Below Average for Sanginita Chemi., Ushanti Colour, Hi-Green Carbon, Arvee Laborat., Vital Chemtech, and the rest. Capital Structure is rated as Good for Arvee Laborat. and Hindcon Chemical, Average for Hi-Green Carbon, and Below Average for Sanginita Chemi., Ushanti Colour, Mahickra Chem., Indian Phosphate, Vital Chemtech, Jocil, Par Drugs & Che., and Nilachal Carbo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sanginita Chemi. at 440.44%, while Hi-Green Carbon has the lowest at -36.05%. Arvee Laborat.'s 1-year return is -0.72%, which is better than Hi-Green Carbon but significantly lower than Sanginita Chemi. Additionally, the six-month returns are negative for Hi-Green Carbon and Hindcon Chemical.

How big is Arvee Laborat.?

As of 14th August, Arvee Laboratories (India) Ltd has a market capitalization of 183.00 Cr and reported net sales of 41.26 Cr and net profit of 4.05 Cr over the latest four quarters.

As of 14th August, <BR><BR>Market Cap: Arvee Laboratories (India) Ltd has a market capitalization of 183.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 41.26 Cr, while the sum of Net Profit for the same period is 4.05 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 31.26 Cr, and Total Assets are valued at 37.57 Cr.

Should I buy, sell or hold Arvee Laboratories (India) Ltd?

Are Arvee Laboratories (India) Ltd latest results good or bad?

Arvee Laboratories (India) Ltd's latest results show strong year-on-year growth with a 642.86% increase in net profit and a 67.44% rise in revenue, but a significant quarterly decline in profitability and margins raises concerns about sustainability. Overall, the results are mixed, reflecting both positive growth and operational challenges.

Arvee Laboratories (India) Ltd's latest results present a mixed picture. In Q4 FY26, the company reported a net profit of ₹0.52 crore, which is a significant year-on-year increase of 642.86% compared to the same quarter last year. However, this figure represents a sharp decline of 71.58% from the previous quarter, indicating considerable volatility in profitability.<BR><BR>On the revenue side, the company achieved ₹10.80 crore, marking a healthy growth of 67.44% year-on-year and a 10.43% increase quarter-on-quarter. This growth in revenue is a positive sign, but it is overshadowed by the substantial drop in net profit and operating margins. The operating margin fell to 10.19%, down from 16.56% in the previous quarter, and the PAT margin decreased dramatically to 4.81% from 18.71%.<BR><BR>Investors reacted positively to the year-on-year profit growth, as evidenced by a 5.46% increase in the stock price following the results announcement. However, the company's high valuation at 84 times trailing earnings and ongoing margin pressures raise concerns about its long-term sustainability.<BR><BR>In summary, while there are positive aspects such as significant year-on-year revenue and profit growth, the sharp quarterly declines in profitability and margins suggest underlying operational challenges. Overall, the results can be seen as good in terms of year-on-year growth but concerning when looking at the quarter-on-quarter performance.

Is Arvee Laborat. overvalued or undervalued?

As of November 17, 2025, Arvee Laboratories is considered overvalued and risky, with a PE ratio of 461.66 and an EV to EBITDA of 171.93, significantly higher than its peers, despite a strong historical stock performance.

As of 17 November 2025, the valuation grade for Arvee Laboratories has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios highlight this concern, with a PE ratio of 461.66, an EV to EBITDA of 171.93, and a ROE of just 1.27%. <BR><BR>In comparison to its peers, Arvee's valuation metrics are starkly higher; for instance, Solar Industries has a PE of 95.31 and Gujarat Fluoroch at 57.85, both categorized as very expensive. The high PE ratio and negative EV to EBIT of -178.80 further underscore the risk associated with Arvee's current valuation. Despite a strong performance over the last five years, where the stock returned 303.78% compared to the Sensex's 102.06%, the current valuation suggests that investors should approach with caution.

How has been the historical performance of Arvee Laborat.?

Arvee Laborat has experienced significant fluctuations in financial performance, with net sales and profits declining from March 2023 to March 2025, despite slight improvements in cash flow. Key metrics such as operating profit and earnings per share also decreased during this period.

Answer:<BR>The historical performance of Arvee Laborat shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Arvee Laborat's net sales have varied considerably, peaking at 62.48 Cr in March 2023 before declining to 38.49 Cr in March 2025. The total operating income followed a similar trend, reaching its highest at 62.48 Cr in March 2023 and dropping to 38.49 Cr in March 2025. The raw material cost has also seen an increase, from 18.87 Cr in March 2025 compared to 16.98 Cr in March 2024, while total expenditure excluding depreciation decreased from 54.07 Cr in March 2023 to 34.87 Cr in March 2025. Operating profit (PBDIT) has fluctuated, with a high of 8.63 Cr in March 2023 and a decrease to 4.28 Cr in March 2025. Profit before tax showed a decline from 6.17 Cr in March 2023 to 2.87 Cr in March 2025, while profit after tax also decreased from 4.12 Cr in March 2023 to 2.15 Cr in March 2025. The earnings per share (EPS) reflected this trend, dropping from 3.74 in March 2023 to 1.95 in March 2025. On the balance sheet, total assets decreased from 38.69 Cr in March 2023 to 38.20 Cr in March 2024, while total liabilities remained relatively stable. Cash flow from operating activities improved slightly from 2.00 Cr in March 2023 to 3.00 Cr in March 2024, with a net cash inflow of 1.00 Cr in March 2024. Overall, the financial performance of Arvee Laborat indicates a challenging period with declining revenues and profits, despite some improvements in cash flow.

What is the technical trend for Arvee Laborat.?

As of June 5, 2025, Arvee Laborat's technical trend is neutral with a slight bearish inclination in the short term, driven by mixed MACD signals and mildly bearish daily moving averages.

As of 5 June 2025, the technical trend for Arvee Laborat has changed from mildly bullish to sideways. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands show a mildly bullish stance on the weekly chart but are sideways on the monthly chart. Moving averages on the daily timeframe are mildly bearish, suggesting short-term weakness. The KST and Dow Theory both indicate a mildly bullish outlook on the weekly and monthly charts. Overall, the current technical stance is neutral with a slight bearish inclination in the short term, driven primarily by the daily moving averages and the mixed signals from the MACD.

Who are the top shareholders of the Arvee Laborat.?

The top shareholders of Arvee Laborat are Shalin Sudhakarbhai Patel, holding 36.68%, and Gitaben Dinehsbhai Patel, with 9.98%. Individual investors collectively own 26.33%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Arvee Laborat include Shalin Sudhakarbhai Patel, who is the promoter with the highest holding at 36.68%. The highest public shareholder is Gitaben Dinehsbhai Patel, holding 9.98%. Additionally, individual investors collectively hold 26.33% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

When is the next results date for Arvee Laborat.?

No Upcoming Board Meetings

What is the bonus history of the Arvee Laborat.?

Arvee Laboratories (India) Ltd issued a 1:1 bonus on October 13, 2020, with a record date of October 14, 2020, allowing shareholders to receive one additional share for each share held.

Arvee Laboratories (India) Ltd has a bonus history that includes a 1:1 bonus issue announced with an ex-date of October 13, 2020. The record date for this bonus was October 14, 2020. This means that shareholders on record as of that date received an additional share for each share they held.

Has Arvee Laborat. declared dividend?

No Dividend History Available